Stockscreener 앱 받기
1.20
4.00%
-0.05
시간 외 거래:
1.20
전일 마감가:
$1.25
열려 있는:
$1.22
하루 거래량:
68,400
Relative Volume:
0.61
시가총액:
$6.67M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-3.23%
1개월 성능:
-31.82%
6개월 성능:
-73.39%
1년 성능:
-92.65%
1일 변동 폭
$1.18
$1.27
1주일 범위
$0.97
$1.53
52주 변동 폭
$0.97
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
명칭
Traws Pharma Inc
전화
267-759-3680
주소
12 PENNS TRAIL, NEWTOWN
TRAW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
1.20 | 6.61M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
236.49 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.32 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.24 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.62 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.09 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-03-01 | 개시 | Ladenburg Thalmann | Buy |
| 2021-05-18 | 개시 | Guggenheim | Buy |
| 2018-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-09 | 개시 | H.C. Wainwright | Buy |
| 2017-04-27 | 개시 | Laidlaw | Buy |
| 2015-07-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | 개시 | H.C. Wainwright | Buy |
모두보기
Traws Pharma Inc 주식(TRAW)의 최신 뉴스
Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments - MSN
Traws Pharma Unveils New Strategic Antiviral Focus - TipRanks
Traws Pharma’s Q1 2025 Results Highlight Progress and Profit - TipRanks
Traws Pharma Reports First Quarter 2025 Results And Business Highlights - marketscreener.com
Traws Pharma Reports Q1 2025 Financial Results - TipRanks
Traws Pharma Reports First Quarter 2025 Results and Business Highlights - GlobeNewswire
Traws Pharma Earnings Surge to $21.5M as Former CDC Director Backs Novel Flu and COVID Drug Pipeline - Stock Titan
Renaissance Technologies LLC Takes $89,000 Position in Traws Pharma, Inc. (NASDAQ:TRAW) - Defense World
Geode Capital Management LLC Makes New $185,000 Investment in Traws Pharma, Inc. (NASDAQ:TRAW) - Defense World
TRAW stock touches 52-week low at $1.51 amid sharp annual decline By Investing.com - Investing.com South Africa
TRAW stock touches 52-week low at $1.51 amid sharp annual decline - Investing.com India
Traws Pharma Appoints New Chairman Amid Leadership Changes - MSN
Traws Pharma appoints new interim CEO with compensation details By Investing.com - Investing.com Canada
Traws Pharma appoints new interim CEO with compensation details - Investing.com Australia
Traws Pharma announces $50 million stock offering potential - Investing.com Australia
Traws Pharma announces $50 million stock offering potential By Investing.com - Investing.com Canada
Traws Pharma Announces Promising Data for Ratutrelvir as a COVID-19 Treatment - MSN
Traws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID Programs - MSN
TRAW stock touches 52-week low at $2.01 amid sharp annual decline By Investing.com - Investing.com South Africa
TRAW stock touches 52-week low at $2.01 amid sharp annual decline - Investing.com India
Traws Pharma CEO Werner Cautreels to retire - MSN
Traws Pharma Reports 2024 Results and Strategic Progress - TipRanks
Traws Pharma Showcases Promising COVID-19 Drug at ICAR Conference - MSN
Earnings call transcript: Traws Pharma Q1 2025 shows innovation boost By Investing.com - Investing.com South Africa
Earnings call transcript: Traws Pharma Q1 2025 shows innovation boost - Investing.com
Traws Pharma Announces Virtual Investor Event to Showcase Innovative Treatments for Bird Flu and COVID-19 - MSN
Traws Pharma Reports 2024 Financial Results and CEO Change - TipRanks
Traws Pharma Reports Full Year 2024 Results and Business Highlights - GlobeNewswire
Traws Pharma's Bird Flu Drug Shows Promise Despite $166M Annual LossKey Updates - Stock Titan
Traws Pharma (TRAW) Expected to Announce Quarterly Earnings on Monday - Defense World
Traws Pharma Announces CEO Transition as Werner Cautreels Retires - MSN
Traws Pharma announces CEO retirement and interim successor By Investing.com - Investing.com South Africa
Traws Pharma announces CEO retirement and interim successor - Investing.com India
Traws Pharma CEO Werner Cautreels Retires, Chair Iain Duke Succeeds on Interim Basis - MarketScreener
Traws Pharma Announces Management Updates - GlobeNewswire
Leadership Shift at Traws Pharma: Chairman Steps Up as CEO Exits, Key Antiviral Programs Continue - Stock Titan
Traws Pharma Reports Promising Preclinical Results for Bird Flu Treatment - MSN
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET - The Manila Times
Traws Pharma to Host Investor Event on Bird Flu and COVID - GlobeNewswire
Former CDC Director Unveils Game-Changing Bird Flu and COVID Treatments at Traws Pharma Event - Stock Titan
Traws Pharma Inc (TRAW) 재무 분석
Traws Pharma Inc (TRAW)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.52%
1.15%
자본화:
|
볼륨(24시간):